| Literature DB >> 35386194 |
Maria A Dimitriu1, Irina Lazar-Contes1, Martin Roszkowski1, Isabelle M Mansuy1.
Abstract
Recent advances in methods for single-cell analyses and barcoding strategies have led to considerable progress in research. The development of multiplexed assays offers the possibility to conduct parallel analyses of multiple factors and processes for comprehensive characterization of cellular and molecular states in health and disease. These technologies have expanded extremely rapidly in the past years and constantly evolve and provide better specificity, precision and resolution. This review summarizes recent progress in single-cell multiomics approaches, and focuses, in particular, on the most innovative techniques that integrate genome, epigenome and transcriptome profiling. It describes the methodologies, discusses their advantages and limitations, and explains how they have been applied to studies on cell heterogeneity and differentiation, and epigenetic reprogramming.Entities:
Keywords: chromatin accessibility; epigenomics; genomics; multiomics; single-cell; transcriptomics
Year: 2022 PMID: 35386194 PMCID: PMC8979110 DOI: 10.3389/fcell.2022.854317
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Individual cell isolation in sc-multiomics. Single-cell multiomics techniques differ in when and how, during their workflow, they isolate single cells into individual reactions for further processing. (A) Different stages at which cells are isolated in sc-multiomics. While some sc-multiomics techniques 1) start from the single-cell suspension by first isolating individual cells (using one of the approaches in (B) and only then subject cells individually to further processing, such as enzymatic treatments (top), other techniques 2) subject the single-cell suspension to enzymatic treatment first and only then isolate single cells (bottom). (B) Different technologies for isolating individual cells in sc-multiomics. Well-based methods rely on techniques such as fluorescence-activated cell sorting (FACS) to sort individual cells into unique wells. Valve microfluidics methods treat single cells individually in unique reaction wells on microfluidic chips. Droplet microfluidics encapsulate individual cells into unique barcoded droplets for further processing.
FIGURE 2Processing of different molecular layers in sc-multiomics. Single-cell multiomics techniques that simultaneously profile the genome and transcriptome of cells differ in the way they process these molecules. (A) Different types of processing of DNA and RNA employed in sc-multiomics depending on the goal of the technique. sc-multiomics techniques differ in the way they process DNA and/or RNA, depending on what the approach aims to profile: DNA can be either treated with M. CviPI (a DNA methyltransferase that methylates cytosine in accessible GC dinucleotides) or with Tn5 (if the aim is to characterize chromatin status), or bisulfite converted (if the aim is DNA methylation profiling), while RNA is subjected to RT and amplification. (B) Simultaneous or parallel processing of DNA and RNA in sc-multiomics. In sc-multiomics, once individual cells are lysed, either 1) DNA and RNA can be first separated from each other using oligo-dT beads and then processed in parallel (left), or 2) the lysed cell can be subjected to DNA tagmentation and RNA reverse transcription (RT) in one reaction, followed by simultaneous pre-amplification of the DNA and cDNA, and then splitting of amplicons into fractions for library preparations (right).
FIGURE 3Use of barcoding at different steps in sc-multiomics. Barcoding of DNA and RNA can be employed at different steps of the processing of single cells, and different labels and techniques can be used at one or more of these steps. A first barcode can be inserted in DNA during tagmentation and in RNA during RT. Then, after pooling of samples and redistribution into wells, one or more ligation-based barcoding is possible. A third barcoding is possible during amplification.
Summary of reviewed single-cell multiomics methods.
| Method | Molecular layers profiled | Throughput (low/medium/high) | Special features (compared to techniques from same category) | Format | References | ||||
|---|---|---|---|---|---|---|---|---|---|
| Epigenome | Genome | Transcriptome | |||||||
| Chromatin accessibility | Chromatin conformation | DNAme | CNVs/ploidy/microsatellites/mutation | poly(A)+ RNA | |||||
|
| x | x | + | ⇑ usable fragments | well |
| |||
|
| x | x | +++ | ⇑ throughput | well |
| |||
|
| x | x | + | ⇓ cost; simple workflow | well |
| |||
|
| x | x | +++ | ⇑ acc. & RNA intersect coverage | well |
| |||
|
| x | x | +++ | ⇑ sensitivity | droplet |
| |||
|
| x | x | ++ | ⇓ price-performance ratio | microfluidics |
| |||
|
| x | x | +++ | ⇑ throughput, performance | well |
| |||
|
| x | x | +++ | ⇑ throughput, performance (esp. ATAC) | well/droplet |
| |||
|
| x | x | + | protein-DNA interactions information | well |
| |||
|
| x | x | + | estimates nucleosome phasing | well |
| |||
|
| x | x | x | + | ⇑ acc. & DNAme intersect coverage | well |
| ||
|
| x | x | ++ | ⇑ accessibility coverage | well |
| |||
|
| x | x | + | ⇑ mapping rate | well |
| |||
|
| x | x | +++ | ⇑ DNAme coverage | well |
| |||
|
| x | x | x | ++ | ⇑ throughput | well |
| ||
|
| x | x | x | + | ⇑ DNAme coverage | well |
| ||
|
| x | x | + | captures total RNA | well |
| |||
|
| x | x | +++ | ⇓ cost; ⇑ throughput | well |
| |||
|
| x | x | + | captures microsatellites | well |
| |||
|
| x | x | x | ++ | ⇑ DNAme coverage | well |
| ||
Throughput: + <500 cells, ++ <2000 cells, +++ >2000 cells. acc. = (chromatin) accessibility. scCAT-seq, single-cell chromatin accessibility and transcriptome sequencing), Paired-seq - parallel analysis of individual cells for RNA, expression and DNA, accessibility by sequencing, sc(ATAC + RNA)-seq - simultaneous chromatin accessibility and gene expression profiling, sci-CAR, single-cell combinatorial indexing-based chromatin accessibility and RNA, SNARE-seq, single-nucleus chromatin accessibility and mRNA, expression profiling; ASTAR-seq, assay for single-cell transcriptome and accessibility regions; SHARE-seq, simultaneous high-throughput ATAC, and RNA, expression with sequencing in single cells; ISSAAC-seq, in situ SHERRY, after ATAC-seq, scDam&T-seq - single-cell DNA, adenine methyltransferase identification (DamID) and messenger RNA, sequencing, scNOMe-seq - single-cell nucleosome occupancy and methylome-sequencing, scCOOL-seq, single-cell chromatin overall omic-scale landscape sequencing, iscCOOL-seq, improved single-cell chromatin overall omic-scale landscape sequencing; scMethyl-HiC, single-cell DNA, methylation and chromatin conformation capture, sn-m3C-seq - single-nucleus methyl-chromatin conformation capture sequencing, scNMT-seq, single-cell nucleosome, methylation and transcription sequencing, scNOMeRe-seq - single-cell nucleosome occupancy, methylome and RNA, expression sequencing; scSIDR-seq, simultaneous isolation and sequencing of genomic DNA, and total RNA, TARGET-seq, single-cell targeted mutational analysis and parallel RNA, sequencing, RETrace - simultaneous retrospective lineage tracing and methylation profiling of single cells, scTrio-seq - single-cell triple omics sequencing.
Recent developments in single-cell multiomics proteome profiling.
| Method | Molecular layers profiled | Proteins profiled | Throughput | References |
|---|---|---|---|---|
|
| proteins and RNA | intranuclear | +++ | Chung et al., 2021 |
|
| proteins and chromatin | surface and intracellular | +++ | Fiskin et al., 2021 |
|
| proteins, RNA and chromatin | surface | +++ | Swanson et al., 2021 |
|
| proteins, RNA and chromatin | surface and intracellular | +++ | Mimitou et al., 2021 |
Throughput: +++ > 2,000 cells. chromatin = chromatin accessibility.
Performance in data quality and coverage achieved by the single-cell multiomics techniques reviewed.
| Method | Genome data | Transcriptome data | DNA methylome data | ||||
|---|---|---|---|---|---|---|---|
| Coverage (# of accessible regions captured per cell) | Mapping rate | Gene detection rate | Exon mapping rate | Mapping rate | Coverage (# of CpGs captured per cell) | Mapping rate | |
|
| 210,000 uniquely mapped fragments/cell | 67% | 8,725 (human) | 54.9% | |||
|
| 2,114 unique reads/nucleus; 1,367 ATAC fragments in peaks | - | 1,481 unique reads/nucleus; 726 UMIs (mouse) | - | - | ||
|
| 1,000–10,000 unique fragments/cell; 40–65% map to peaks | - | 1,500–3,000 genes/cell (human) | 1.6% | 61% | ||
|
| 1,456 unique reads; 915 ATAC fragments in peaks | - | 3,276 UMIs (mouse) | - | - | ||
|
| 2,720/nucleus; 1,059 ATAC fragments in peaks | 91% | 623 UMIs (mouse) | 37% | 94% | ||
|
| 142,886 library size; 27.9% fragments in peaks | 86% | >15% (9,739) (human) | >75% | 73.8% | ||
|
| 7,805 ATAC fragments in peaks; 65.5% fragments in peaks | - | 9,290 UMIs (mouse) | - | - | ||
|
| 58,000 unique reads in peaks; 37% fragments in peaks | >17,000 UMIs (mouse); >4,000 genes (mouse) | 35–60% | ||||
|
| - | - | 2,282 genes (mouse) | - | - | ||
|
| 6.7 million GpCs/cell; 20,388 DHSs | 52% | 1.3 million CpGs/cell | - | |||
|
| 2,800 NDRs/cell; 19.7 million GCH; aggregate: 77.2% | 22% | 2.2 million WCGs (10.1%); agg.: 67.4% | - | |||
|
| Aggregate: 84.7% of GCH | 62% | Aggregate: >80% of CpG sites | - | |||
|
| 80,763 informative contacts per nucleus (150 cells) | - | 567,380 CpGs/nucleus | - | |||
|
| 500,000 contacts/cell (4,200 cells) | - | 27.5% of mouse genome | 72% | |||
|
| 15% of GpCs; 75% of promoters, 85% of gene bodies probed | - | - | - | - | 22.8% of mouse genome | 32% |
|
| 31 million GCH; 15.5% per cell | - | 10,000–15,000 genes (mouse) | - | - | 3.49 million WCG (15.8%) | - |
|
| - | >90% | 5,690 genes (human) | 87% | - | ||
|
| Detected all mutations in 98.4% of cells | - | 8,200 genes (human) | - | - | ||
|
| 1,217 microsatellites/cell | - | 146,000 CpGs/cell | - | |||
|
| - | 8,106 genes (human) | - | - | 16.4 million CpGs/cell | - | |
Grey blocks = molecular layer not profiled by the technique. - = molecular layer is profiled by the technique, but data is not provided. The methylation status of GCH, sites (GCA/GCT/GCC) is used to analyze chromatin accessibility, while the methylation status of WCG, sites (ACG/TCG) is used to analyze the endogenous DNA, methylation.